Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
Exec appointment
confidence 95%
filed 2026-09-09
Item 5.02
Genuine Parts Company appointed Court Carruthers as Chief Executive Officer-Elect, effective September 8, 2026, with assumption of the full CEO role upon completion of the planned separation in Q1 2027. The appointment includes compensatory arrangements with a base salary of $1,000,000, bonus targets, and equity grants totaling $6,000,000 in 2026 and $7,200,000 upon assuming full CEO role. Additionally, Bert Nappier was appointed Chief Operating Officer and James Howe as Chief Operating Officer of Motion, each with associated compensation adjustments.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-09-09
Item 5.02
CME Group announced multiple senior executive appointments: Jack Tobin to Deputy CFO (November 2026) and then CFO (March 2027), Matthew Render to Chief Accounting Officer (November 2026), and John Marchese to General Counsel (September 2026). These are material C-suite appointments affecting the company's financial and legal leadership structure. While Tobin's appointment involves a transition from his prior role as Chief Accounting Officer, the principal disclosed action is his promotion to CFO and joining the Management Team, making this an appointment event.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-09-09
Item 5.02
Peter G. Clifford was appointed by the Board of Directors as Executive Vice President and Chief Financial Officer, effective September 21, 2026, with a base salary of $700,000, 90% bonus target, $1,950,000 long-term incentive target, and inducement awards of performance-based RSUs and stock options.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-09-09
Item 5.02
The disclosure centers on the election and appointment of Fazal F. Merchant as a Director of AT&T Inc., effective September 8, 2026, to fill a vacancy created by the Board's expansion from 10 to 11 members. While the section also mentions his committee assignments and participation in the standard non-employee director compensation program, the principal disclosed action is the appointment of a new director to the Board.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-09-09
Item 5.02
David Bailey was appointed Chief Commercial Officer of STAAR Surgical effective September 8, 2026, reporting to the CEO and joining the executive committee. His compensation package includes a base salary of CHF 462,825, target bonus of 60%, initial equity grant of $850,000 in RSUs, and a 2026 long-term incentive award of $1,400,000. Bailey, a former CEO and President of International Operations, is expected to play a strategic role in the company's commercial execution and growth initiatives.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-09-09
The filing discloses the appointment of David J. Goldschmidt to the Board of Directors and the Audit Committee, effective September 8, 2026. The principal disclosed action is a person taking a role as director and committee member, with specified compensation arrangements ($150,000 annual cash retainer plus $150,000 annual stock award, plus $20,000 for Audit Committee service). This is a material governance event affecting board composition.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-09-09
Item 7.01
Turn Therapeutics announced the appointment of Robert R. Redfield, M.D., former CDC Director, as Chief Scientific Officer. The press release emphasizes his four decades of experience in immunology and infectious disease, his extensive scientific publications, and his prior leadership roles at the CDC and University of Maryland. This is a material executive appointment of a high-profile scientific leader to a named officer position at the company.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 92%
filed 2026-09-09
Christopher Cooper was appointed Chief Executive Officer effective September 3, 2026, following Katie Field's resignation as Interim CEO. While the filing discloses both a departure and an appointment, the principal disclosed action is the appointment of a new CEO—a material executive leadership change. The detailed biographical information and the fact that Cooper was elevated from existing director to CEO underscore the materiality of this appointment to investors.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 95%
filed 2026-09-09
EX-99.1
Aurora Cannabis announces the appointment of Faris El Refaie as Executive Vice President, Global Commercial, effective September 28, 2026. This is a newly created executive role with responsibility for the company's global commercial function, medical cannabis market strategy, and international expansion across Canada, Europe, Australia, and New Zealand. The appointment of a seasoned biopharmaceutical executive to a senior leadership position overseeing global commercial operations is material to investors assessing the company's strategic direction and management capability.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-09-09
The filing discloses the appointment of Joshua S. Lev and Michael Fox as co-Chief Executive Officers and Presidents of electroCore, effective September 8, 2026, along with their appointment as Class III Board members. While the filing also includes compensatory arrangements (salary increases, RSU grants) and severance policy amendments, the principal disclosed action centers on the appointment of two executives to the CEO role. The press release emphasizes this as a "deliberate leadership and succession process" resulting in a "shared leadership structure," making the appointment the salient event.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 95%
filed 2026-09-09
EX-99.1
Draganfly announces the appointment of Colonel (Ret'd) Kevin Leblond as Vice-President, Canadian Defence and Security. This is a clear executive appointment to a named officer position. The appointment is material because Leblond brings 29 years of senior military experience and will lead the company's Canadian defence business during a period of defence modernization, directly supporting the company's strategic growth in a key market segment.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-09-09
Item 5.02
Michael Brous was appointed Chief Financial Officer of Lyft effective September 28, 2026, replacing retiring CFO Erin Brewer. The appointment includes substantial compensatory arrangements totaling approximately $4.2 million in base salary, RSU grants, a promotion grant, and PSU grants.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 75%
filed 2026-09-09
Item 5.02
Chunsen Song was appointed as a director and President, Asia-Pacific Region, effective September 9, 2026. Song, who serves as CEO and Chairman of Zhongke Haichuang (the target of the proposed acquisition), brings extensive experience in IoT, digital commerce, and new energy businesses to lead the company's Asia-Pacific expansion.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-09-09
Item 5.02
Margaret Whitman was appointed as a Board member effective September 8, 2026, and elected to the newly created role of Executive Chair. The filing emphasizes her appointment and expanded board responsibilities, with Kim Fennebresque transitioning from Chair to Lead Independent Director. While the disclosure includes compensatory details ($100,000 base salary and $8.9 million in RSUs), the principal disclosed action centers on Whitman taking on the Executive Chair role—a significant executive appointment at a major retailer.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-09-09
Item 5.02
Essential Properties Realty Trust announced multiple executive appointments and promotions: R. Max Jenkins was promoted to President and Chief Operating Officer; Robert W. Salisbury's role was expanded to include Chief Strategy Officer; and Craig Vachris was appointed as Chief Investment Officer. A. Joseph Peil departed from his executive role.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-09-09
Item 5.02
The Board appointed Sergey Novikov as Principal Accounting Officer effective September 2, 2026. Although Mr. Novikov had served as Controller since June 2021 and as acting principal accounting officer from December 2024 to May 2025, this disclosure centers on his formal appointment to the principal accounting officer role, a key financial leadership position. The appointment of a principal accounting officer is material to investors' assessment of financial reporting oversight and governance.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-09-08
Item 5.02
Sean M. Salmon was elected and appointed to Teleflex's Board of Directors effective September 8, 2026, with appointment to the Growth and Operating Committee. Salmon brings over 30 years of medical device and pharmaceutical experience, including 21 years at Medtronic as Executive Vice President and President of Cardiovascular, and the Board emphasized his strategic expertise in capital allocation, portfolio strategy, and operational execution.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-09-08
Item 5.02
Brian Stringham's appointment as Senior Vice President and Corporate Controller (the Bank's principal accounting officer) effective September 7, 2026, is the principal disclosed action. While Jason Arbuckle's transition to Senior Director of Corporate Finance and Transformation is also mentioned, the focus of the disclosure is Stringham's appointment to a senior officer role overseeing accounting and regulatory reporting. This is material as it involves a change in the registrant's principal accounting officer.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-09-08
Item 5.02
Anil Chakravarthy was appointed President and Chief Executive Officer of Adobe effective December 1, 2026, and elected to the Board of Directors. Shantanu Narayen transitioned to Executive Chair, and David Wadhwani departed. The Board unanimously determined Chakravarthy is the right leader for Adobe's next chapter of growth.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 93%
filed 2026-09-08
Item 5.02
Robert Kuhns was appointed as Executive Vice President and Chief Financial Officer of MSC Industrial Direct Co Inc, effective September 14, 2026, bringing 30+ years of financial expertise and prior CFO experience at TopBuild Corp. The appointment includes a $650,000 base salary, $1.5M sign-on equity grant, and change-of-control severance provisions. Greg Clark's resignation as Interim CFO is also disclosed in connection with this permanent appointment.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 98%
filed 2026-09-08
EX-99.1
The exhibit announces the appointment of Jonathan M. Pratt as Chief Executive Officer of QIAGEN, effective September 1, 2026, succeeding Thierry Bernard. This is a material executive appointment at the highest level of the organization. The disclosure includes Pratt's extensive background (25+ years in life sciences and laboratory technologies, most recently as CEO of Filtration Group), the Supervisory Board's unanimous endorsement, and his planned proposal for shareholder approval as Managing Director at an Extraordinary General Meeting in Q4 2026. The appointment of a new CEO is a material event affecting investor assessment of company leadership and strategic direction.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 75%
filed 2026-09-08
Item 5.02
Thomas S. Gayner appointed to the additional role of Chairman effective September 8, 2026, succeeding Steven A. Markel. Simon Wilson appointed as Co-President and CEO of Markel Insurance, and Andrew G. Crowley appointed as Co-President and CEO of Markel Ventures, representing a significant leadership transition at the top of the organization.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-09-08
Item 5.02
The filing centers on the appointment of Ms. Sumita Pandit as Senior Vice President and Chief Financial Officer effective September 9, 2026, with detailed disclosure of her background, employment agreement terms (including $750,000 base salary, $3,000,000 one-time bonus, and equity awards totaling $5,350,000 in PSUs and RSUs), and severance provisions. While Mr. Weiner's departure as CFO is also disclosed, the principal action and the bulk of the disclosure focuses on Pandit's appointment to this material executive role. The appointment of a new CFO is material to investors as it affects the registrant's financial leadership and governance.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 85%
filed 2026-09-08
The filing announces the appointment of Metin Tuğtağ as Chief Sales Officer effective September 9, 2026, following the resignation of Kadri Özdal. While both a departure and appointment occur, the principal disclosed action is the appointment of a named executive to a C-suite role (Chief Sales Officer). The appointment of a CSO is material to investors as it affects the company's sales leadership and strategy.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-09-08
Item 5.02
Michele Harradence was appointed as President and Chief Executive Officer effective January 1, 2027, and concurrently appointed to the Board of Directors, succeeding retiring CEO Greg Ebel following a multi-year succession planning process. This represents a material executive leadership transition at the major energy infrastructure company.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 93%
filed 2026-09-08
Item 5.02
AdaptHealth appointed Harriss Currie as Chief Financial Officer effective September 9, 2026, with a base salary of $670,000, 100% target bonus, and $818,462 in RSUs. The appointment replaces Jason Clemens' departure as CFO and represents a material change in the company's financial leadership.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-09-08
Item 5.02
Serge Zappone was appointed as President, International and Senior Vice President of Allegion, effective January 1, 2027, succeeding Timothy P. Eckersley and reporting to the CEO.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-09-08
Item 5.02
Steven Ryder was appointed as Chief Financial Officer of Clearway Energy, Inc., effective October 1, 2026, succeeding Sarah Rubenstein. Samantha Prout was also appointed as SVP Accounting and Controller (principal accounting officer). Sarah Rubenstein transitioned to Head of Transformation Office at the parent company.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-09-08
Item 5.02
Steven Ryder was appointed as Chief Financial Officer of Clearway Energy LLC effective October 1, 2026, succeeding Sarah Rubenstein. Simultaneously, Samantha Prout was appointed as Senior Vice President, Accounting and Controller, effective immediately, also succeeding Rubenstein in her principal accounting officer role. These appointments represent material changes to the company's financial leadership.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-09-08
Item 5.02
The filing discloses the appointment of Brent Moen as Chief Financial Officer effective September 11, 2026, with detailed compensation arrangements including a $475,000 base salary, bonus opportunity, and $500,000 long-term incentive award. While the section also mentions Matthew McDonnell's transition from CFO to Head of Australia, the principal disclosed action centers on the appointment of a new CFO, a material executive position. This is a clear exec_appointment event.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-09-08
Item 5.02
Shutterstock appointed three new directors—Timothy Adams, Matthew Salzberg, and Michael Thompson—to its Board of Directors, effective September 8, 2026, as Class II and Class III directors based on the Nominating Committee's recommendation. The appointees bring extensive financial, operational, investment, and technology expertise to strengthen the Board's governance.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-09-08
Item 5.02
Northern Technologies International Corp announced a planned executive succession effective September 4, 2026, with Gautam Ramdas appointed as President and Chief Executive Officer and elected to the Board, Brian Haglund appointed as Chief Operating Officer, G. Patrick Lynch transitioning from CEO to Chairman, and Richard Nigon appointed as lead independent director. The appointments include compensation arrangements for the new executives.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 95%
filed 2026-09-08
EX-99.1
The exhibit announces the appointment of Martin Dewhurst to NovaBridge's Board of Directors as an independent director and member of the Audit and Compensation Committees, effective immediately. This is a clear governance event involving the appointment of a named executive/director with substantial healthcare and board experience. The disclosure also notes the concurrent departure of independent director Liu Xin, but the principal action disclosed is Dewhurst's appointment to the board and committees.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-09-08
Item 5.02
The filing discloses the appointment of Jennifer Fulk as Chief Financial Officer, principal financial officer, and principal accounting officer of Kura Oncology, effective September 8, 2026. While the disclosure includes compensatory details (base salary of $550,000, bonus eligibility, equity awards of 450,000 options and 173,438 PSUs, and severance provisions), the principal action is the appointment of a named executive officer to a key financial leadership role. This is material to investors as CFO changes affect financial oversight and governance.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 75%
filed 2026-09-08
Aatish V Patel ceased serving as President of XCHG Limited and was appointed General Manager of the Company's wholly-owned U.S. subsidiary, XCharge Energy USA Inc., effective September 7, 2026. While this involves both a departure from one role and an appointment to another, the filing emphasizes the appointment to the subsidiary leadership position as the principal action, framed as a strategic reassignment to strengthen U.S. operations. The amendment to his offer letter and the material nature of a President-level executive's repositioning make this material to investors assessing management continuity and strategic direction.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-09-08
Item 5.02
Thomas Civik was appointed as permanent Chief Executive Officer and Chairman of the Board, effective September 4, 2026, transitioning from his interim role since February 2026. The appointment includes compensatory arrangements (stock option grant and sign-on bonus), severance terms, and related governance changes including John Flavin's transition to Lead Independent Director and Dr. Palani's resignation.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 75%
filed 2026-09-08
Item 5.02
Glenn Boehnlein was appointed to the Board of Directors effective September 4, 2026, bringing significant financial and medical-technology sector expertise. Concurrently, Board Chair Boon Hwee Koh retired on the same date, and Dow R. Wilson was elected as the new Board chair.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-09-08
Item 5.02
The Board appointed Benjamin Graboske as a Class III director effective immediately, with a term expiring at the 2027 Annual Meeting. This is a clear director appointment disclosed under Item 5.02. While the section also mentions director compensation arrangements, the principal disclosed action is the appointment itself, not a compensation modification. The appointment is material as it expands the Board from six to seven members and affects governance structure.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-09-08
Item 5.02
Xponential Fitness appointed Jennifer Ryu as Chief Financial Officer, effective October 19, 2026, succeeding interim CFO Robert Julian. The appointment includes a base salary of $550,000, target bonus of 60%, sign-on bonus of $150,000, and equity grants valued at $1.7 million.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-09-08
Item 7.01
Three executives were promoted effective October 1, 2026: Gary Campbell to President, Americas; Brian Hatcher to President, Recon, S.E.T., CMFT, Neuro and Biosurgery; and Bradley Kessler to President, Americas – Robotics, Technology and Data. All three will report directly to the CEO as part of a leadership restructuring designed to streamline operations.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-09-08
The filing discloses the appointment of Christopher Jensen as Chief Executive Officer and Board member effective September 8, 2026, along with concurrent compensatory arrangements (base salary $450,000, performance bonus, and RSU eligibility). While Edward Chen's resignation as CEO is also mentioned, the principal disclosed action centers on Jensen's appointment to lead day-to-day operations of a Nasdaq-listed company. The filing also discloses a concurrent employment agreement with CFO Young Cho, but Jensen's CEO appointment is the primary event. This is material to investors as it represents a significant leadership change at a recently public company (IPO in June 2026).
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-09-08
Item 5.02
Michael P. Pell was elected as an Ohio member director of the Federal Home Loan Bank of Cincinnati's board of directors for a four-year term commencing January 1, 2027, confirming board leadership continuity.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-09-08
Item 5.02
Kiora Pharmaceuticals appointed Keith Lane as Executive Vice President, Head of Clinical Development and Regulatory Affairs, effective September 8, 2026. Lane brings 20+ years of ophthalmology experience and previously served as Chief Scientific Officer at Ora, Inc. The appointment includes compensatory terms of $350,000 base salary, $75,000 sign-on bonus, 35% performance bonus target, and 55,000 stock options.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-09-08
Item 7.01
Loop Industries announced the appointment of Jeffrey R. Geygan as Chairman of the Board of Directors, with founder and CEO Daniel Solomita retaining his CEO role but relinquishing the Chairman title. This represents a material governance change involving the appointment of a new board leader with significant capital-markets and public-company experience, coupled with a structural separation of the Chairman and CEO roles. The press release emphasizes this as strengthening corporate governance and enabling focused commercial execution.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-09-08
Item 5.02
David Garcia Rios was appointed as a Class II director of the Board, effective September 2, 2026, exercising SFF's contractual board designation right under the January 2026 Investors' Rights Agreement. Garcia Rios brings expertise in digital assets and corporate governance to the cryptocurrency-focused company.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-09-08
The filing discloses the promotion of Thomas Englese to Chief Commercial Officer of Tonix Pharmaceuticals, effective immediately on September 8, 2026. Englese had previously served as Executive Vice President of Commercial Operations since September 2024 and will now lead the company's commercial organization overseeing sales, marketing, and market access for TONMYA and other marketed products. This is a material executive appointment to a C-suite officer role at a commercial-stage biopharmaceutical company.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-09-08
Timothy A. Peterman was appointed as Acting CFO of Laser Photonics Corporation on September 8, 2026, replacing Ralph Venegas who resumed his prior position as VP of Finance and Reporting. This is a material executive appointment disclosed under Item 5.02, as the CFO is a named executive officer whose appointment affects investor assessment of the company's financial leadership and governance.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 92%
filed 2026-09-08
The filing discloses the appointment of Martín de los Ríos Plaza as a Regular Director for Class D shares by the Supervisory Committee, replacing the resigned director Maximiliano D'Alessio. While the resignation is also mentioned, the principal disclosed action is the appointment of a new director to fill the vacancy. Board-level director appointments are material governance events affecting the composition of the registrant's leadership.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-09-08
Item 5.02
Simeon Kohl was appointed as Chief Executive Officer, President, principal executive officer, principal operating officer, and Board member of Health Catalyst, Inc., effective September 14, 2026. Ben Albert transitioned from CEO to Chief Business Officer in connection with this succession. Kohl brings over 20 years of healthcare leadership experience, including his track record at Performant Healthcare.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-09-08
Item 5.02
John M. Sullivan has been appointed to VICI Properties' Board of Directors as an independent director, effective upon regulatory approvals. The disclosure centers on the principal action of a person taking a board role, with details on his committee assignments and qualifications. This is a clear exec_appointment event. The appointment is material as it affects board composition and governance at a large S&P 500 REIT.
View raw filing on EDGAR →